Yposkesi, a CDMO specializing in cell and gene therapies, launched project SKY, the construction of a second commercial cell and gene therapy facility and new global resource for drug developers of biologics, also called ATMPs (Advanced Therapy Medicinal Products). ATMPs treat patients living with rare and life-threatening diseases.   In March 2021 SK Pharmteco, a global CDMO, became a new majority equity shareholder in Yposkesi backed by an investment of approximately $71 million in the new 5...